1. Home
  2. QURE
  3. QURE News

Latest uniQure N.V. (QURE) News on September 12, 2025

Lake Street: AMT-130 Could Be Game-Changer For ClearPoint
QURE

Insider Monkey

3 months ago

Lake Street: AMT-130 Could Be Game-Changer For ClearPoint

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
QURE

GlobeNewswire

3 months ago

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

Lake Street says AMT-130 could be ‘significantly impactful’ for ClearPoint
QURE

TipRanks

3 months ago

Lake Street says AMT-130 could be ‘significantly impactful’ for ClearPoint

QURE

MT Newswires

3 months ago

UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
QURE

GlobeNewswire

3 months ago

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
QURE

GlobeNewswire

3 months ago

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
QURE

GlobeNewswire

4 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?
QURE

Zacks

4 months ago

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ...
QURE

GuruFocus.com

4 months ago

uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ...

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
QURE

Zacks

4 months ago

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

QURE

Associated Press Finance

4 months ago

UniQure: Q1 Earnings Snapshot

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
QURE

GlobeNewswire

4 months ago

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

uniQure to Announce First Quarter 2025 Financial Results
QURE

GlobeNewswire

4 months ago

uniQure to Announce First Quarter 2025 Financial Results

CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?
QURE

Zacks

4 months ago

CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?
QURE

Zacks

5 months ago

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

FDA grants breakthrough status to uniQure’s Huntington’s disease therapy
QURE

Pharmaceutical Technology

5 months ago

FDA grants breakthrough status to uniQure’s Huntington’s disease therapy

QURE

MT Newswires

5 months ago

Top Midday Gainers

QURE

MT Newswires

5 months ago

Update: UniQure Shares Rise After Gene Therapy for Huntington's Gets FDA Breakthrough Designation

QURE

MT Newswires

5 months ago

UniQure's Huntington's Drug Gets FDA Breakthrough Therapy Designation

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
QURE

GlobeNewswire

5 months ago

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

QURE

MT Newswires

6 months ago

Uniqure Insider Sold Shares Worth $291,629, According to a Recent SEC Filing

uniQure Full Year 2024 Earnings: Misses Expectations
QURE

Simply Wall St.

6 months ago

uniQure Full Year 2024 Earnings: Misses Expectations

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
QURE

Zacks

7 months ago

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
QURE

GlobeNewswire

7 months ago

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%
QURE

Simply Wall St.

7 months ago

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
QURE

Benzinga

7 months ago

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
QURE

PR Newswire

7 months ago

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

QURE

MT Newswires

7 months ago

UniQure Advances AMT-191 Trial in Fabry Disease

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
QURE

GlobeNewswire

7 months ago

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

QURE

MT Newswires

7 months ago

UniQure Gets Favorable Recommendation From Data Monitoring Committee AMT-162 Trial to Treat Amyotrophic Lateral Sclerosis

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
QURE

GlobeNewswire

7 months ago

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts?
QURE

Insider Monkey

8 months ago

Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts?

Here’s Why uniQure N.V. (QURE) Is Skyrocketing
QURE

Insider Monkey

8 months ago

Here’s Why uniQure N.V. (QURE) Is Skyrocketing

Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025?
QURE

Insider Monkey

8 months ago

Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025?

QURE

MT Newswires

8 months ago

uniQure Prices $75 Million Public Offering; Shares Fall

uniQure Announces Pricing of its Public Offering
QURE

GlobeNewswire

8 months ago

uniQure Announces Pricing of its Public Offering

QURE

MT Newswires

8 months ago

uniQure Launches Public Offering of Shares, Pre-Funded Warrants

QURE

MT Newswires

8 months ago

UniQure Files Mixed Shelf; Shares Fall After Hours

uniQure Announces Proposed Public Offering
QURE

GlobeNewswire

8 months ago

uniQure Announces Proposed Public Offering

QURE

MT Newswires

8 months ago

RBC Raises Price Target on uniQure to $24 From $20, Keeps Outperform, Speculative Risk

uniQure price target raised to $32 from $12 at Stifel
QURE

TipRanks

9 months ago

uniQure price target raised to $32 from $12 at Stifel

Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
QURE

Motley Fool

9 months ago

Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?

QURE

MT Newswires

9 months ago

Uniqure Insider Sold Shares Worth $1,503,000, According to a Recent SEC Filing

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
QURE

Zacks

9 months ago

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
QURE

Zacks

9 months ago

Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More

QURE

MT Newswires

9 months ago

RBC Raises Price Target on uniQure to $20 From $14, Keeps Outperform, Speculative Risk

QURE

MT Newswires

9 months ago

UniQure Gets Rating Upgrade From Wells Fargo After Agreement With FDA -- Shares Continue Rally

UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug
QURE

Investor's Business Daily

9 months ago

UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
QURE

Investor's Business Daily

9 months ago

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug

QURE

MT Newswires

9 months ago

UniQure Says Aligned With FDA on Approval Pathway for Huntington's Disease Drug; Shares Jump

UniQure shares soar on chance of speedy approval for Huntington’s therapy
QURE

BioPharma Dive

9 months ago

UniQure shares soar on chance of speedy approval for Huntington’s therapy

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
QURE

GlobeNewswire

9 months ago

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

Is uniQure N.V. (NASDAQ:QURE) Trading At A 39% Discount?
QURE

Simply Wall St.

9 months ago

Is uniQure N.V. (NASDAQ:QURE) Trading At A 39% Discount?

Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet
QURE

Zacks

9 months ago

Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet

What Makes uniQure (QURE) a New Buy Stock
QURE

Zacks

9 months ago

What Makes uniQure (QURE) a New Buy Stock

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
QURE

GlobeNewswire

10 months ago

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade
QURE

Zacks

10 months ago

Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade

What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates
QURE

Simply Wall St.

10 months ago

What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates

uniQure Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
QURE

Simply Wall St.

10 months ago

uniQure Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
QURE

Zacks

10 months ago

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates

QURE

Associated Press Finance

10 months ago

UniQure: Q3 Earnings Snapshot

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
QURE

GlobeNewswire

10 months ago

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth
QURE

Zacks

10 months ago

Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth

UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
QURE

Zacks

10 months ago

UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

State Street Corp's Strategic Reduction in uniQure NV Holdings
QURE

GuruFocus.com

a year ago

State Street Corp's Strategic Reduction in uniQure NV Holdings

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
QURE

GlobeNewswire

a year ago

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
QURE

GlobeNewswire

a year ago

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
QURE

Zacks

a year ago

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?

QURE

MT Newswires

a year ago

UniQure's Gets Orphan Drug Designation From FDA for Fabry Disease Treatment

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
QURE

GlobeNewswire

a year ago

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure (NASDAQ:QURE) investors are sitting on a loss of 88% if they invested five years ago
QURE

Simply Wall St.

a year ago

uniQure (NASDAQ:QURE) investors are sitting on a loss of 88% if they invested five years ago

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
QURE

GlobeNewswire

a year ago

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
QURE

Simply Wall St.

a year ago

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

UniQure restructuring to claim 300 jobs
QURE

BioPharma Dive

a year ago

UniQure restructuring to claim 300 jobs

UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
QURE

Zacks

a year ago

UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates

QURE

Associated Press Finance

a year ago

UniQure: Q2 Earnings Snapshot

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
QURE

GlobeNewswire

a year ago

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?
QURE

Zacks

a year ago

Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?

QURE

MT Newswires

a year ago

UniQure Completes Sale of Facility to Genezen

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
QURE

GlobeNewswire

a year ago

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

uniQure’s shares soar on positive data for Huntington’s gene therapy
QURE

Clinical Trials Arena

a year ago

uniQure’s shares soar on positive data for Huntington’s gene therapy

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
QURE

Zacks

a year ago

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
QURE

Zacks

a year ago

Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet

uniQure (QURE) Soars on New Huntington's Disease Study Data
QURE

Zacks

a year ago

uniQure (QURE) Soars on New Huntington's Disease Study Data

uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?
QURE

Zacks

a year ago

uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?

Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)
QURE

Zacks

a year ago

Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)

UniQure stock surges on data for Huntington’s gene therapy
QURE

BioPharma Dive

a year ago

UniQure stock surges on data for Huntington’s gene therapy

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
QURE

GlobeNewswire

a year ago

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 52%
QURE

Simply Wall St.

a year ago

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 52%

QURE

MT Newswires

a year ago

uniQure's Commercial Gene Therapy Operations to be Acquired by Genezen

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
QURE

PR Newswire

a year ago

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
QURE

GlobeNewswire

a year ago

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

UniQure, with sale of plant, outsources Hemgenix manufacturing
QURE

BioPharma Dive

a year ago

UniQure, with sale of plant, outsources Hemgenix manufacturing

QURE

MT Newswires

a year ago

UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
QURE

GlobeNewswire

a year ago

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease

uniQure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
QURE

Simply Wall St.

a year ago

uniQure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

QURE

Associated Press Finance

a year ago

UniQure: Q1 Earnings Snapshot

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
QURE

GlobeNewswire

a year ago

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

13 Best Biotech Stocks To Buy Under $20
QURE

Insider Monkey

a year ago

13 Best Biotech Stocks To Buy Under $20

uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates
QURE

Simply Wall St.

2 years ago

uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates

Share on Social Networks: